Want to find out if you've got ovarian cancer? Then Aspira Women's Health's OvaWatch could be for you.
The Intercept reports OvaWatch is an AI-based blood test for ovarian cancer that's currently in clinical trials.
It's one of a number of new tests Aspira is developing for conditions such as endometriosis, which is caused by abnormal tissue growth in the uterus.
Aspira CEO Nicole Sandford says ovarian cancer is a "huge, huge market" and OvaWatch is expected to be a "game-changer" in women's health.
The test is based on a protein-based blood test that's been shown to detect ovarian cancer, according to a press release.
Aspira is also developing an AI-based endometriosis test called EndoMDX.
It's currently in the final stages of design for a microRNA signature to identify endometriosis and expects to complete verification in 2024, Sandford says.
Aspira reported Q4 revenue of $2.1 million, flat with Q4 2022 but up 15% year-over-year.
For the full year, revenue was $9.2 million, up 15%.
The company reported a 49% drop in cash used in 2023 to $9.15 million, according to InvestingPro.
Read the Entire Article
A customized collection of news from foundations from around the Web.
HootSuite CEO Ryan Holmes says “…social tools are getting more broadly adopted across organizations. It’s not just marketing anymore, it’s sales, public relations, human relations, everywhere.”